Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE ANHYDROUS POTASSIUM SULFATE SODIUM SULFATE versus SODIUM PICOSULFATE MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE ANHYDROUS POTASSIUM SULFATE SODIUM SULFATE versus SODIUM PICOSULFATE MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID.
MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE vs SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Osmotic laxative that retains water in the bowel lumen via osmotic gradient, inducing diarrhea to cleanse the colon. Sodium sulfate, potassium sulfate, and magnesium sulfate are poorly absorbed, creating an osmotic effect. Additionally, magnesium may stimulate cholecystokinin release.
Sodium picosulfate is a stimulant laxative that is converted by colonic bacteria to the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane, which acts on the colonic mucosa to stimulate peristalsis and increase water and electrolyte secretion. Magnesium oxide and citric acid react in solution to form magnesium citrate, an osmotic laxative that draws water into the intestinal lumen, increasing stool volume and promoting bowel evacuation.
For bowel cleansing prior to colonoscopy: 3 packets (each packet contains 1.6 g magnesium sulfate anhydrous, 3.13 g potassium sulfate, and 1.5 g sodium sulfate) dissolved in water to make 16 ounces, followed by additional water: administer as a split-dose regimen (one 16-ounce solution the evening before and one 16-ounce solution on the day of the procedure).
Adults: 10 mg sodium picosulfate, 3.5 g magnesium oxide, and 10.97 g anhydrous citric acid (reconstituted in water) as a single oral dose, followed by clear liquids. Two doses may be used in a split-dose regimen: first dose evening before procedure, second dose day of procedure at least 5 hours prior.
None Documented
None Documented
Not applicable as a systemic half-life; the drug acts locally in the gastrointestinal tract. For absorbed sulfate, elimination half-life is approximately 6-8 hours in patients with normal renal function.
Sodium picosulfate active metabolite BHPM: terminal half-life approximately 7.4 hours; clinical duration of laxative effect extends beyond half-life due to colonic residence.
Primarily renal excretion. Approximately 20% of sulfate is absorbed and excreted in urine; the remainder is eliminated fecally as unabsorbed drug. Potassium is mostly reabsorbed; excess is excreted renally.
Sodium picosulfate is primarily excreted in feces (biliary/fecal elimination) as active metabolite BHPM; <5% renal. Magnesium oxide is excreted renally as magnesium ions; absorbed magnesium is eliminated via kidneys. Anhydrous citric acid is metabolized in the Krebs cycle; minimal renal excretion.
Category C
Category C
Laxative
Laxative